Evotec's Cash Runway Question Hangs Over a Half-Year Report Full of Shifting Timelines

Evotec faces liquidity worries with cash runway to April 2027, weak H1 results, and slow cost savings; shares near 52-week low.

The market chatter around Evotec has taken a distinctly uncomfortable turn. Unconfirmed speculation is circulating that the Hamburg-based biotech and pharma services group may only be funded through April 2027, with a possible capital increase arriving as soon as summer of next year. The alleged culprit: persistent cash burn that shows no sign of abating. Nothing has been officially confirmed, but the rumours have landed in a marketplace already rattled by last week's numbers.

The figures themselves tell a story of a company in transition, though not necessarily the one management had hoped for. Second-quarter revenue slipped to €143.5 million, a 16.2 percent decline year-on-year. That brought first-half sales to €300.1 million, down 19.2 percent, with adjusted EBITDA stuck at minus €42.7 million. The bottom line was even uglier: a net loss of €168.6 million, burdened by €98.9 million in reorganisation charges and a €42.3 million impairment on a laboratory building in Hamburg.

What's particularly telling for the financing debate is the pace of the so-called Horizon transformation. CEO Christian Wojczewski has indicated the restructuring programme will likely deliver only 20 to 30 percent of its targeted €75 million in annual savings this year. For anyone hoping for rapid cost relief, that timeline is sobering — and it feeds directly into concerns about the group's medium-term liquidity position.

There is, however, a sliver of encouraging news buried in the operational detail. The Drug Discovery & Preclinical Development segment saw net revenue climb by more than 28 percent. The weakness, it appears, is not universal; rather, shifted milestones at existing partnerships are doing much of the damage to the consolidated figures. Management attributes roughly 40 percent of the revenue cut versus prior guidance to revised project phases, with the corresponding income now not expected until 2027.

That deferral dynamic is central to understanding the current predicament. Evotec has confirmed its July-reduced guidance for 2026 — revenue of €570 million to €610 million and an adjusted EBITDA loss between €70 million and €105 million. The confirmation offers no fresh hope, merely a restatement of the pain already communicated two months ago.

The market's response has been predictably cautious. The shares trade around €3.34 to €3.35, roughly 1.2 percent lower on the day and about 18 percent beneath the 50-day moving average of €4.07. The distance to the 52-week low of €3.19, touched in mid-July, is now a mere 5 percent. Year-to-date, the stock has shed approximately 38 to 39 percent depending on the day's close — a decline that speaks to the depth of investor disillusionment.

Adding another layer of scrutiny is the artificial intelligence partnership with Odyssey Therapeutics. Market participants are questioning whether the collaboration can deliver the hoped-for financial tailwind given the looming capital constraints, or whether it might instead tie up additional investment without generating near-term cash flow.

Analyst reactions have been mixed. TD Cowen downgraded the stock from "Buy" to "Hold" on Tuesday, while H.C. Wainwright trimmed its earnings estimates following the half-year release. RBC Capital Markets remains the outlier with a €10.00 price target and an "Outperform" rating — though that call dates from the day of the results and may soon face revision given the new rumour mill.

In a separate development, Camilla Macapili Languille departed the supervisory board on August 7, a personnel change that lands at an awkward moment for a company already under intensified observation from both investors and the operational side.

The Horizon programme itself is described by management as running to plan, with the expected 20 to 30 percent of annual savings materialising this year. Whether that proves sufficient to restore confidence is another matter entirely — the cost-cutting effort is colliding with a revenue decline that has structural roots, not merely cyclical ones.

For shareholders, the calculus is unenviable. If the capital increase speculation proves accurate, existing investors face dilution on top of an already punishing year. If it remains just a rumour, attention may swing back to operational execution and the tangible progress of Horizon. Until the company issues its next official statement, the uncertainty — and the volatility that comes with it — is likely to persist. The shares, caught between a growing discovery business and postponed partnership revenues, will probably remain a plaything of expectations regarding just how much of those milestones actually slip into 2027.